medline.ch Respirationstrakt Neoplasie

	A prognostic analysis of lung cancer surgery in super-elderly patients: a multicenter real-world data study. Surg Today Hayama M, Okazaki M, Suzawa K, Shien K, Fujiwara T, Hirami Y, Watanabe M, Okutani D, Nishikawa H, Ueno T, Otani S, Matsuda E, Yaginuma H, Toyooka S. PMID: 42496895 [PubMed - as supplied by publisher]
	Brief report: attitudes and barriers toward genetic testing in pleural mesothelioma: a nationwide Italian survey. Fam Cancer Cerbone L, Perrino M, Grosso F, Ganzinelli M, Lo Russo G, Pasello G, Zucali PA, Ceresoli GL, Occhipinti M, Sculco M, on the behalf of MET-I (Mesothelioma team Italy). PMID: 42496771 [PubMed - indexed for MEDLINE]
	Development and Internal Validation of a Patient-Level Diagnostic Model Integrating Folate Receptor-Positive Circulating Tumor Cells and Peripheral CD8 Count for Malignant-Versus-Benign Pathology Discrimination in a Pathology-Enriched Pulmonary Nodule Cohort. Thorac Cancer Zhang C, Sun X, Su H, Liu Y, Gong L, Ma X, Zhang W, Sun F. PMID: 42496100 [PubMed - indexed for MEDLINE]
	Primary and acquired resistance to immunotherapy in NSCLC. Front Immunol Yuan B, Deng W, Luo J, Xin Y, Jiang X, Liu X, Cai Q. PMID: 42495623 [PubMed - indexed for MEDLINE]
	Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer. Front Immunol Chen W, Liang Y, Hou Q, Cao X, Zhao A, Wu B, Zhou Y, Zhang W, Zhao M, Yao N, Li F, Duan J, Zhang S, Li N, Cao J. PMID: 42495622 [PubMed - indexed for MEDLINE]
	Circulating immune and biochemical markers predict tumor response to immunotherapy in advanced melanoma and lung cancer. Front Immunol Sequero-Lopez S, Castillo-Barnes D, Gálvez-Carvajal L, Palazón-Carrión N, Martínez-Murcia FJ, de la Cruz-Merino L, Muñoz-Couselo E, Provencio M, Ortiz A, Górriz JM, Ramírez J, Rueda-Domínguez A, Blancas I. PMID: 42495619 [PubMed - indexed for MEDLINE]
	Price trend, clinical benefit and within-class competition of drugs for metastatic Non-small cell lung cancer in China: a retrospective cohort study. Lancet Reg Health West Pac Du X, Luo X, Zhang H, Shen T, Wang X, Guo Q, Lv X, Zhao X, Pu Y, Yang Y, Huang L, Zhang Y. PMID: 42495089 [PubMed]
	Editorial: Advancing diagnostic excellence in early lung cancer detection. Front Oncol Kim RY, Kammer MN, Kim YW. PMID: 42494589 [PubMed]
	An interpretable multi-task whole-slide histopathology AI model for non-small cell lung cancer: Cross-cohort generalisation, spatial attention-transcriptomic integration, and molecular-immune profiling. Clin Transl Med Lu R, Lin A, Jiang A, Feng Y, Fang X, Shen J, Bai Y, Peng S, Zhang J, Cheng Q, Feng S, Li Q, Luo P. PMID: 42494157 [PubMed - indexed for MEDLINE]
	Radiological pure-solid appearance clinical stage I lung adenocarcinoma: a comparative study of mucinous and non-mucinous adenocarcinoma based on imaging features and survival outcomes. Insights Imaging Li W, Du H, Wu S, Wang J, Song N, Wan Z, Wu F, Shi J. PMID: 42493663 [PubMed]
	Integration of hierarchical clustering in hematologic biomarkers prediction for endocrine toxicity during immunotherapy in lung cancer patients. Sci Rep Coniac S, Ionescu RT, Costache-Outas MC, Antone-Iordache IL, Barbu AM, Bardan VT, Zamfir A, Ionescu AI, Badiu C. PMID: 42493517 [PubMed - indexed for MEDLINE]
	A clinical tool for early mortality risk stratification in colorectal cancer patients with liver or lung metastases: A retrospective cohort study. Curr Probl Surg Chen H, Liu Z, Wang Z, Lin D. PMID: 42493190 [PubMed - in process]
	Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer. Eur J Cancer Nguyen D, Lee SH, Lu S, Girard N, Lin CC, Felip E, Aguilar A, Charoentum C, Cruz FM, Akamatsu H, Kowalyszyn R, Arslan C, Forster MD, Urban D, Misch D, Montes LVG, Gadgeel SM, Cruz-Correa M, Owen S, Schuette W, Sermon J, Kerßenboom R, Frosien M, Meißner J, Ord P, Ennis M, Fennema E, Sethi S, Bauml JM, Daksh M, Cho BC. PMID: 42492306 [PubMed - as supplied by publisher]
	Pan-immune-inflammation value as a prognostic and predictive biomarker in metastatic non-small cell lung cancer treated with nivolumab: A real-world study. Oncol Lett Turan N, Yildiz HS, Yildirim S, Turkoglu E, Ozkerim U, Oksuz S, Buyukmurat N, Bal H, Surmeli H, Odabas H. PMID: 42491228 [PubMed]
	The impact of whole lung irradiation in lung metastatic rhabdomyosarcoma: A pooled analysis of two European trials and one European registry. Cancer Heinz AT, Heesen P, Merks JHM, Minard-Colin V, Ebinger M, Cameron AL, Harrabi S, Mandeville H, Schoot RA, Fuchs J, Guillen G, Koscielniak E, Chisholm JC, Sparber-Sauer M, Bisogno G. PMID: 42490727 [PubMed - indexed for MEDLINE]
	Barriers and facilitators to uptake lung cancer screening using low-dose computed tomography scan in high-risk people in Vietnam. Transl Behav Med Van Tran D, Van Le Q, Le Ngo L, Van Hoang D, Anh Trong Dam V, Khac Nguyen K, Thanh Thi Tran H, Manh Do H, Hong Luu H, Thanh Thi Nguyen X, Son Choi K. PMID: 42490697 [PubMed - indexed for MEDLINE]
	The current status of health literacy among caregivers of lung cancer patients:A cross-sectional survey. PLoS One Lei L, Jiang Y, Feng G, Li J, Wu D, Wang X, Xue X. PMID: 42490661 [PubMed - indexed for MEDLINE]
	Receipt of cancer care among stage IV non-small-cell lung cancer patients with and without intellectual or developmental disabilities: A population-based retrospective cohort study. Palliat Med Hansford RLW, Davis LE, Griffiths R, Horrill T, Nguyen P, Goldie CL, Hanna TP, Mahar AL. PMID: 42490651 [PubMed - as supplied by publisher]
	Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan's Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer. Drugs Real World Outcomes Nakatsui M, Nishida Y, Nozue S, Sakata Y, Azuma M, Abe R, Okamoto R, Nakagami Y, Okuno Y. PMID: 42489799 [PubMed - as supplied by publisher]
	Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study. Clin Cancer Res Niknafs N, Sivapalan L, Balan A, Wehr J, Pereira G, Hosseini-Nami S, Rao N, Jolly S, Velliangiri K, Beadles I, Loftus T, Chesnick B, Medina J, Xiao W, Pabani A, Marrone KA, Li QK, Murray JC, Rinaldi L, Dracopoli NC, Sausen M, Hann CL, Scott SC, Feliciano J, Lam VK, Levy B, Velculescu VE, Brahmer JR, Forde PM, Vellanki PJ, Anagnostou V. PMID: 42489696 [PubMed - as supplied by publisher]

Artikel 1 - 20 / 161742

Seite 1 von 8088



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung